Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China · Delayed Price · Currency is CNY 14.91
+0.39 (2.69%)
Aug 20, 2026, 3:00 PM CST
Cisen Pharmaceutical Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,751 | 7,842 | 6,221 | 6,601 | 5,668 | 5,978 | |
Market Cap Growth | -56.21% | 26.05% | -5.76% | 16.46% | -5.19% | -4.03% |
Enterprise Value | 3,181 | 4,581 | 3,782 | 4,082 | 3,364 | 3,917 |
Last Close Price | 14.91 | 17.12 | 13.25 | 13.49 | 11.35 | 11.73 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.56 | 18.61 | 12.22 | 12.66 | 16.20 | 17.89 |
Forward PE | - | 46.95 | 46.95 | 46.95 | 46.95 | 46.95 |
PS Ratio | 2.00 | 2.28 | 1.56 | 1.48 | 1.39 | 1.58 |
PB Ratio | 1.06 | 1.26 | 1.04 | 1.15 | 1.06 | 1.18 |
P/TBV Ratio | 1.10 | 1.31 | 1.08 | 1.20 | 1.11 | 1.23 |
P/FCF Ratio | 12.54 | 19.53 | 13.26 | 15.23 | 25.40 | 32.74 |
P/OCF Ratio | 11.22 | 16.81 | 10.90 | 14.63 | 21.94 | 25.59 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.94 | 1.33 | 0.95 | 0.92 | 0.83 | 1.03 |
EV/EBITDA Ratio | 7.01 | 9.82 | 5.68 | 5.22 | 6.47 | 9.07 |
EV/EBIT Ratio | 12.12 | 16.91 | 8.51 | 7.41 | 11.55 | 18.28 |
EV/FCF Ratio | 5.91 | 11.41 | 8.06 | 9.41 | 15.08 | 21.45 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 |
Debt / EBITDA Ratio | 0.09 | 0.09 | 0.17 | 0.22 | 0.30 | 0.33 |
Debt / FCF Ratio | 0.08 | 0.11 | 0.25 | 0.39 | 0.71 | 0.79 |
Net Debt / Equity Ratio | -0.57 | -0.54 | -0.45 | -0.45 | -0.49 | -0.45 |
Net Debt / EBITDA Ratio | -8.00 | -7.21 | -4.03 | -3.33 | -5.05 | -5.28 |
Net Debt / FCF Ratio | -6.71 | -8.37 | -5.71 | -6.01 | -11.76 | -12.49 |
Asset Turnover | 0.44 | 0.46 | 0.54 | 0.63 | 0.62 | 0.60 |
Inventory Turnover | 2.48 | 2.42 | 2.39 | 2.97 | 3.11 | 2.96 |
Quick Ratio | 3.98 | 3.63 | 2.72 | 3.02 | 3.17 | 2.86 |
Current Ratio | 4.65 | 4.26 | 3.33 | 3.63 | 3.70 | 3.40 |
Return on Equity (ROE) | 6.61% | 6.97% | 8.76% | 9.45% | 6.77% | 6.78% |
Return on Assets (ROA) | 2.15% | 2.23% | 3.73% | 4.87% | 2.76% | 2.14% |
Return on Invested Capital (ROIC) | 8.03% | 7.52% | 12.29% | 16.48% | 10.17% | 7.92% |
Return on Capital Employed (ROCE) | 4.00% | 4.30% | 7.30% | 9.20% | 5.30% | 4.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.05% | 5.37% | 8.18% | 7.90% | 6.17% | 5.59% |
FCF Yield | 7.97% | 5.12% | 7.54% | 6.57% | 3.94% | 3.05% |
Dividend Yield | 2.20% | 2.03% | 3.32% | 3.23% | 2.95% | 2.56% |
Payout Ratio | 44.76% | 43.42% | 59.85% | 29.95% | 39.87% | 36.13% |
Buyback Yield / Dilution | -0.02% | 0.31% | -0.23% | 0.25% | -0.65% | 0.18% |
Total Shareholder Return | 2.14% | 2.35% | 3.09% | 3.49% | 2.30% | 2.74% |